Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering
Melbourne (Australia) 9th November 2017 – Telix Pharmaceuticals Limited has successfully raised $50 million following the close of its fully underwritten Initial Public Offering
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by institutional investors internationally and domestically, as well as by retail investors in Australia.
The full press release can be found here.